Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 1000+ Conferences, 1000+ Symposiums and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.
Explore and learn more about Conference Series Ltd: World’s leading Event Organizer
Daptomycin is the first of a new class of antibiotics, the cyclic lipopeptides. It exerts bactericidal action via depolarization of the cell membrane in a rapid (<1 hour) and concentration-dependent manner with a post-antibiotic effect. It possesses broad activity against Gram-positive pathogens, such as Streptococcus, Staphylococcus (including methicillin-resistant isolates), and Enterococcus faecalis/E. faecium (including vancomycin-resistant isolates). Daptomycin is currently approved by FDA for the treatment of 1) complicated skin and skin structure infections (4 mg/kg/day) caused by S. aureus (including methicillin-resistant isolates), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus dysgalactiaesubspecies equisimilis, and Enterococcus faecalis (vancomycin-susceptible isolates only), and 2) S. aureus bacteremia (6 mg/kg/day), including those with right-sided infective endocarditis, caused by methicillin-susceptible and methicillin-resistant isolates. Because daptomycin is inactivated by surfactant in the lung, so it should not be used for the treatment of respiratory infections.
OMICS Group International through its Open Access Initiative is committed to make genuine and reliable contributions to the scientific community. OMICS Group hosts over 350 leading-edge peer reviewed Open Access journalsand has organized over 100 scientific conferences all over the world. OMICS Publishing Group journals have over 3 million readers and the fame and success of the same can be attributed to the strong editorial board which contains over 30000 eminent personalities and the rapid, quality and quick review processing. OMICS Group Conferences make the perfect platform for global networking as it brings together renowned speakers and scientists across the globe to a most exciting and memorable scientific event filled with much enlightening interactive sessions, world class exhibitions and poster presentations.
Importance and scope:
Antibiotics-2015 is the premier event that brings together a unique and International mix of experts, researchers and decision makers from both academia and industry across the globe to exchange their knowledge, experience and research innovations. There is a renewed interest in the antibiotic sector, which is evident from the most recent patents and investments. Bacterial vaccines and new antibiotic classes are gaining a tremendous amount of attention with several product candidates in clinical development. This conference focuses exclusively on antibiotics, bacterial vaccines, and other emerging antibacterial
New technologies and the outsourcing of antibiotics to lower-cost countries will slow the recent annual increases in expenditures in the U.S. to a 3.3% compound annual growth rate (CAGR) over the forecast period. Clinical trial spending in 2010 is an estimated $25 billion and is expected to reach $28.5 billion by 2014. The report provides an overview of clinical development phases, the regulatory issues involved, and the factors influencing clinical trial costs. An overview is provided of new technologies that will be affecting the clinical trial process in the near future.
This page will be updated regularly.
This page was last updated on 09th Sep, 2015
1-702-508-5200 Ext:8031, 8041
1-702-508-5200 Ext:8045, 8047
Immunology & Microbiology Conferences
Nursing and Healthcare Conferences
Clinical and Biochemistry Conferences
1-702-508-5200 Ext:8031, 8037
Material Science Conferences
Genetics & Mol Biology Conferences
Media Partners | Advertising